Cargando…
Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
STUDY OBJECTIVES: To asses the long-term safety and efficacy of pitolisant, an histamine H3-receptor antagonist, on narcolepsy. METHODS: This open-label, single-arm, pragmatic study, recruited adult patients with narcolepsy and Epworth Sleepiness Scale (ESS) score ≥12. After a titration period, pati...
Autores principales: | Dauvilliers, Yves, Arnulf, Isabelle, Szakacs, Zoltan, Leu-Semenescu, Smaranda, Lecomte, Isabelle, Scart-Gres, Catherine, Lecomte, Jeanne-Marie, Schwartz, Jean-Charles |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802569/ https://www.ncbi.nlm.nih.gov/pubmed/31529094 http://dx.doi.org/10.1093/sleep/zsz174 |
Ejemplares similares
-
Evaluation of the abuse potential of pitolisant, a selective H(3)-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
por: Setnik, Beatrice, et al.
Publicado: (2019) -
Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial
por: Dauvilliers, Yves, et al.
Publicado: (2020) -
Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023) -
Update on the treatment of narcolepsy: clinical efficacy of pitolisant
por: Calik, Michael W
Publicado: (2017) -
Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021)